ReviewClinical interventions in aging2025
The Protective Activity of Apigenin Against Bone and Cartilage Diseases.
Review in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Classification, Structure-Activity Relationship, and Anti-Osteoarthritis Mechanism of Natural Flavonoids.Chemistry & biodiversity · 2026Review
- The "Tianyu" Formulation Alleviates Rheumatoid Arthritis by Modulating the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Targeting the osteoimmune microenvironment to prevent regulated chondrocyte death in osteoarthritis: therapeutic potential of natural products.Frontiers in cell and developmental biology · 2026Review
- Apigenin accelerates fracture healing by enhancing endochondral differentiation and inflammation resolution via targeting NF-κB signaling.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone and cartilage diseases have become the leading causes of joint disability due to the destruction of bone and cartilage. No effective drugs are available to cure bone and cartilage diseases. Exploring natural compounds as therapeutic alternatives shows promise. Apigenin, a naturally occurring flavonoid, exhibits various pharmacological activities, such as anti-inflammation, antioxidant, and immune modulation. Apigenin acts as a phytoestrogen and mediates the balance of bone remodeling by inducing osteogenic differentiation, promoting osteoblast-associated bone formation, and inhibiting osteoclast-related bone resorption. In addition, apigenin exhibits protective effects against osteoporosis (OP), rheumatoid arthritis (RA), osteoarthritis (OA), gouty arthritis (GA), and intervertebral disc degeneration (IDD). Apigenin can be a promising agent in treating bone and cartilage. However, the application of apigenin is limited due to its low water solubility and bioavailability. More efforts are still needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.